Patents by Inventor Michelle Hortter

Michelle Hortter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20220213226
    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-?. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-?. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-? antigen binding proteins, and pharmaceutical formulations thereof.
    Type: Application
    Filed: July 19, 2021
    Publication date: July 7, 2022
    Applicant: AMGEN INC.
    Inventors: Hailing HSU, Gunasekaran KANNAN, Kenneth W. WALKER, Michelle HORTTER, Edward J. BELOUSKI
  • Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
    Patent number: 11104745
    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-?. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-?. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-? antigen binding proteins, and pharmaceutical formulations thereof.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 31, 2021
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Gunasekaran Kannan, Kenneth W. Walker, Michelle Hortter, Edward J. Belouski
  • ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20190119407
    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-?. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-?. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-? antigen binding proteins, and pharmaceutical formulations thereof.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 25, 2019
    Applicant: AMGEN INC.
    Inventors: Hailing HSU, Gunasekaran KANNAN, Kenneth W. WALKER, Michelle HORTTER, Edward J. BELOUSKI
  • TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20180237542
    Abstract: The present invention relates to tetravalent bispecific and tetraspecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the bispecific and tetraspecific antigen binding proteins as well as methods for producing them are also disclosed.
    Type: Application
    Filed: September 15, 2016
    Publication date: August 23, 2018
    Applicant: AMGEN INC.
    Inventors: Gunasekaran KANNAN, Michelle HORTTER, Edward J. BELOUSKI
  • WISE BINDING AGENTS AND EPITOPES
    Publication number: 20120288507
    Abstract: The present invention relates to binding agents for WISE, and includes methods for their manufacture and use.
    Type: Application
    Filed: December 17, 2010
    Publication date: November 15, 2012
    Applicant: Amgen Inc.
    Inventors: Xueming Qian, Aaron George Winters, Michelle Hortter, Kevin Graham, Mei-Mei Tsai